Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 1Hypertension 1Hot Flashes 1Diabetes Mellitus 1Depressive Disorder, Major 1Depression 1Cardiovascular Diseases 1Breast Neoplasms 1

Interventions

Nutrition Assessment 4Bevacizumab 3Lisinopril 2Labetalol 2Hydrochlorothiazide 2Angiotensin-Converting Enzyme Inhibitors 2ziprasidone 1pazopanib 1ganirelix 1enzalutamide 1clevidipine 1bicalutamide 1benazepril 1aliskiren 1Zolpidem 1Warfarin 1Vitamin D 1Vecuronium Bromide 1Vancomycin 1Urine Specimen Collection 1Tumor Necrosis Factors 1Tranexamic Acid 1Tobramycin 1Thiazides 1Therapeutics 1Surveys and Questionnaires 1Sunitinib 1Sulindac 1Standard of Care 1Spironolactone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hypertension × Desvenlafaxine Succinate × Clear all
NCT01803711 2017-12-27

Omega 3 FA Supplements as Augmentation in the Treatment of Depression

UConn Health

Phase 2/3 Terminated
6 enrolled 4 charts

Cardiovascular Diseases, Depression, Depressive Disorder, Major, Diabetes Mellitus, Hypertension, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡